News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 673 results
April 2012
-
Media ReleaseNovartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand nameNow available in US pharmacies, Hecoria (tacrolimus) capsules are approved for the prevention of organ rejection in certain kidney and liver transplant patientsHecoria, a branded generic, complements…
-
Media ReleaseNovartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
March 2012
-
Media ReleaseNovartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease- Arcapta Neohaler is the only once-daily, 24-hour long-acting beta2-agonist approved for maintenance treatment of airflow obstruction in COPD patients- Arcapta Neohaler showed significant…
-
Media ReleaseNovartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
January 2012
-
Media ReleasePlaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims- Company to resolve wage and hour claims with one-time payment of up to 99 million dollars for eligible class members- Novartis Pharmaceuticals Corporation remains committed to compensate all…
-
Media ReleasePlaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
December 2011
-
Media ReleaseNovartis Pivotal Study of Exjade® Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia- Trial shows Exjade, an iron chelator, is significantly better than placebo at reducing liver iron concentration in patients with NTDT- Non-transfusion-dependent thalassemia (NTDT) is a genetic…
-
Media ReleaseNovartis Pivotal Study of Exjade® Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia
-
Media ReleaseTwo Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®- ENESTcmr data show 23% of patients switched to Tasigna achieved undetectable levels of Bcr-Abl within 12 months compared to 11% who continued on Gleevec(1)- Three-year ENESTnd data show 32% of…
-
Media ReleaseTwo Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
November 2011
-
Media ReleaseNovartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis- Chronic steroid use to treat the symptoms of systemic juvenile idiopathic arthritis (SJIA) can contribute to slowed growth and delayed puberty[2],[3]- The new pivotal Phase III data also showed…
-
Media ReleaseNovartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Pagination
- ‹ Previous page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- …
- 57
- › Next page